servaenergy.comCrawled Nov 9, 2026
Actinium-225 is a promising isotope for targeted cancer therapy, but supply is scarce. See how Serva plans to scale production.
How medical isotope production works, and why Actinium-225 supply is a key constraint for radiopharmaceutical therapy.
Serva Energy highlights healthcare innovations in nuclear medicine at Arizona Bioscience Week.
Serva Energy’s CEO discusses energy independence as a strategic response to geopolitical and climate challenges.
Serva Energy supports U.S. isotope production efforts, including the new Stable Isotope Production and Research Center.
Updates, media coverage, and insights on Actinium-225 and isotope production from the Serva team.
Serva Energy develops a method to produce Actinium-225, a cancer-treatment isotope, using a commercial nuclear reactor.
Serva Energy is selected to participate in the White Hat Life Science Investor Conference during Arizona Bioscience Week.
Interested in advancing Actinium-225 isotope production? Serva welcomes inquiries from future team members.
Serva is a nuclear technology company focused on producing Actinium-225 for targeted radiopharmaceutical therapy.
Request investor information, explore a partnership, or contact the Serva team.
Serva Energy offers a free bimonthly newsletter with updates from leadership and upcoming projects.
Serva is building a new production path for Actinium-225, a promising isotope for targeted cancer therapy.
Serva Energy discusses the history and potential of Actinium-225 as a cancer treatment on the *Drug Discovery News* podcast. The conversation highlights the isotope’s role in advancing targeted therapies for oncology. The company’s expertise in radiopharmaceuticals is emphasized in the discussion.
May 2024Serva EnergyNews article
Serva Energy collaborates with the **University of California—Irvine Nuclear Reactor Facility** to develop nuclear research expertise. The partnership supports hands-on training for students and early-career scientists in nuclear science applications. This initiative aligns with broader efforts to expand the next generation of professionals in advanced energy technologies.
Apr 2024Serva EnergyNews article
MIT confirms Serva Energy’s method for producing the rare medical isotope **Actinium-225 (Ac-225)**, used in cancer treatments. The validation follows Serva Energy’s sample measurement, marking a potential breakthrough in isotope production for targeted therapies. Ac-225 is critical for precision oncology due to its alpha-emitting properties.
Nov 2023PR NewswireNews article
Serva Energy demonstrates nuclear innovation at the Nuclear Science Week expo event hosted by the University of California—Irvine. The company showcases advancements in nuclear technology during the national exposition.
Oct 2023Serva EnergyNews article
